SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes

SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes

Purpose Metastatic castration-resistant prostate cancer (mCRPC) remains a significant therapeutic challenge and a leading cause of cancer-related mortality in men. PARP inhibitors like Olaparib are effective in homologous recombination repair (HRR)-deficient tumors, but resistance often arises throu...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Zhao, Shiyun Feng, Xiaoping Nitie, Shibu Muluo, Yi Lei
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Cancer Biology & Therapy
Subjects:
mCRPC
SLX1
parpi
Olaparib
Online Access:https://www.tandfonline.com/doi/10.1080/15384047.2025.2545062
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items